Toad glandular secretions and skin extractions as anti-inflammatory and anticancer agents

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Qi, Ji ^a   Tan, C K ^a   Hashimi, Saeed M ^a   Zulfiker, Abu Hasanat Md ^a   Good, David ^a,b   Wei, Ming Q ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ARENOBUFAGIN; BUFALIN; BUFOTALIN; CARDIAC GLYCOSIDE; CHANSU; CINOBUFAGIN; CINOBUFOTALIN; CYCLOOXYGENASE 2; CYTOMEGALOVIRUS ANTIGEN PP65; GAMABUFOTALIN; HUACHANSU; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; NUCLEAR FACTOR KAPPA B 2; PROSTAGLANDIN E2; PROTEIN P50; PROTEIN P52; PROTEIN P60; RECINOBUFAGIN; TELOCINOBUFAGIN; TISSUE EXTRACT; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BUFO BUFO; CANCER PREVENTION; CHINESE MEDICINE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN GLAND;

EID: 84896472859     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/312684     Document Type: Review

References (102)

1. Balkwill F., Mantovani A., Inflammation and cancer: back to virchow? The Lancet 2001 357 9255 539 545 2-s2.0-0035901090 10.1016/S0140-6736(00)04046-0 (Pubitemid 32173595)
2. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A., Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009 30 7 1073 1081 2-s2.0-67650151005 10.1093/carcin/bgp127
3. Hagemann T., Balkwill F., Lawrence T., Inflammation and cancer: a double-edged sword. Cancer Cell 2007 12 4 300 301 2-s2.0-35148874235 10.1016/j.ccr.2007.10.005 (Pubitemid 47539316)
4. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., Taniyama K., Sasaki N., Schlemper R. J., Helicobacter pylori infection and the development of gastric cancer. The New England Journal of Medicine 2001 345 11 784 789 2-s2.0-0035856021 10.1056/NEJMoa001999
5. Naugler W. E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A. M., Karin M., Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007 317 5834 121 124 2-s2.0-34447327216 10.1126/science.1140485 (Pubitemid 47056470)
6. Jess T., Loftus E. V. Jr., Velayos F. S., Harmsen W. S., Zinsmeister A. R., Smyrk T. C., Schleck C. D., Tremaine W. J., Melton L. J. III, Munkholm P., Sandborn W. J., Risk of intestinal cancer in inflammatory bowel disease: A Population-Based Study from Olmsted County, Minnesota. Gastroenterology 2006 130 4 1039 1046 2-s2.0-33645998460 10.1053/j.gastro.2005.12.037
7. De Marzo A. M., Platz E. A., Sutcliffe S., Xu J., Grönberg H., Drake C. G., Nakai Y., Isaacs W. B., Nelson W. G., Inflammation in prostate carcinogenesis. Nature Reviews Cancer 2007 7 4 256 269 2-s2.0-33947687854 10.1038/nrc2090 (Pubitemid 46486616)
8. Multhoff G., Molls M., Radons J., Chronic inflammation in cancer development. Frontiers in Immunology 2012 2 98
9. Gupta R. A., DuBois R. N., Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Reviews Cancer 2001 1 1 11 21 2-s2.0-0035496616 (Pubitemid 33741877)
10. Coussens L. M., Werb Z., Inflammation and cancer. Nature 2002 420 6917 860 867 2-s2.0-0037180757 10.1038/nature01322 (Pubitemid 36019639)
11. Burke F., Relf M., Negus R., Balkwill F., A cytokine profile of normal and malignant ovary. Cytokine 1996 8 7 578 585 2-s2.0-0030198856 10.1006/cyto.1996.0077 (Pubitemid 26294548)
12. Mantovani A., Garlanda C., Allavena P., Molecular pathways and targets in cancer-related inflammation. Annals of Medicine 2010 42 3 161 170 2-s2.0-77950825019 10.3109/07853890903405753
13. Karin M., Greten F. R., NF- B: linking inflammation and immunity to cancer development and progression. Nature Reviews Immunology 2005 5 10 749 759 2-s2.0-25844459154 10.1038/nri1703 (Pubitemid 41400849)
14. Lee C. H., Jeon Y.-T., Kim S.-H., Song Y.-S., NF- B as a potential molecular target for cancer therapy. BioFactors 2007 29 1 19 35 2-s2.0-34250898562 10.1002/biof.5520290103 (Pubitemid 46985299)
15. Luqman S., Pezzuto J. M., NF B: a promising target for natural products in cancer chemoprevention. Phytotherapy Research 2010 24 7 949 963 2-s2.0-77954520406 10.1002/ptr.3171
16. Yamamoto Y., Gaynor R. B., Therapeutic potential of inhibition of the NF- B pathway in the treatment of inflammation and cancer. Journal of Clinical Investigation 2001 107 2 135 142 2-s2.0-0035139792 (Pubitemid 32096826)
17. Da Rocha A. B., Lopes R. M., Schwartsmann G., Natural products in anticancer therapy. Current Opinion in Pharmacology 2001 1 4 364 369 2-s2.0-0035433799 10.1016/S1471-4892(01)00063-7 (Pubitemid 33585985)
18. Yadav V. R., Prasad S., Sung B., Kannappan R., Aggarwal B. B., Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins 2010 2 10 2428 2466 2-s2.0-79952084572 10.3390/toxins2102428
19. Clarke B. T., The natural history of amphibian skin secretions, their normal functioning and potential medical applications. Biological Reviews of the Cambridge Philosophical Society 1997 72 3 365 379 2-s2.0-0030689711 10.1017/S0006323197005045 (Pubitemid 27453597)
20. Weiss U., Inflammation. Nature 2008 454 7203 427 2-s2.0-47949133729 10.1038/454427a
21. Mariotti A., A primer on inflammation. Compendium of Continuing Education in Dentistry 2004 25 7, supplement 1 7 15
22. Hart J., Inflammation. 1: its role in the healing of acute wounds. Journal of Wound Care 2002 11 6 205 209 2-s2.0-0036598961
23. Mantovani A., Allavena P., Sica A., Balkwill F., Cancer-related inflammation. Nature 2008 454 7203 436 444 2-s2.0-47949096781 10.1038/nature07205
24. Balkwill F., Coussens L. M., Cancer: an inflammatory link. Nature 2004 431 7007 405 406 2-s2.0-4644335311 10.1038/431405a (Pubitemid 39329565)
25. Mantovani A., Garlanda C., Allavena P., Molecular pathways and targets in cancer-related inflammation. Annals of Medicine 2010 42 3 161 170 2-s2.0-77950825019 10.3109/07853890903405753
26. Borrello M. G., Alberti L., Fischer A., Degl'Innocenti D., Ferrario C., Gariboldi M., Marchesi F., Allavena P., Greco A., Collini P., Pilotti S., Cassinelli G., Bressan P., Fugazzola L., Mantovani A., Pierotti M. A., Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proceedings of the National Academy of Sciences of the United States of America 2005 102 41 14825 14830 2-s2.0-26844576749 10.1073/pnas.0503039102 (Pubitemid 41457140)
27. Aggarwal B. B., Shishodia S., Sandur S. K., Pandey M. K., Sethi G., Inflammation and cancer: how hot is the link? Biochemical Pharmacology 2006 72 11 1605 1621 2-s2.0-33750497844 10.1016/j.bcp.2006.06.029 (Pubitemid 44666739)
28. Aggarwal B. B., Vijayalekshmi R. V., Sung B., Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clinical Cancer Research 2009 15 2 425 430 2-s2.0-59449085264 10.1158/1078-0432.CCR-08-0149
29. Luo J.-L., Kamata H., Karin M., IKK/NF- B signaling: balancing life and death-a new approach to cancer therapy. Journal of Clinical Investigation 2005 115 10 2625 2632 2-s2.0-26444605834 10.1172/JCI26322 (Pubitemid 41434385)
30. Baud V., Karin M., Is NF- B a good target for cancer therapy? Hopes and pitfalls. Nature Reviews Drug Discovery 2009 8 1 33 40 2-s2.0-58149202128 10.1038/nrd2781
31. Karin M., Nuclear factor- B in cancer development and progression. Nature 2006 441 7092 431 436 2-s2.0-33745298519 10.1038/nature04870 (Pubitemid 44050137)
32. Yu Y. Y., Li Q., Zhu Z. G., NF- B as a molecular target in adjuvant therapy of gastrointestinal carcinomas. European Journal of Surgical Oncology 2005 31 4 386 392 2-s2.0-17144390219 10.1016/j.ejso.2004.10.010 (Pubitemid 40521305)
33. Yang G., Yu F., Fu H., Lu F., Huang B., Bai L., Zhao Z., Yao L., Lu Z., Identification of the distinct promoters for the two transcripts of apoptosis related protein 3 and their transcriptional regulation by NFAT and NF B. Molecular and Cellular Biochemistry 2007 306 1-2 187 194 2-s2.0-35549010598 10.1007/s11010-007-9572-9 (Pubitemid 350001839)
34. Pikarsky E., Porat R. M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Uriell-Shoval S., Galun E., Ben-Neriah Y., NF- B functions as a tumour promoter in inflammation-associated cancer. Nature 2004 431 7007 461 466 2-s2.0-4644324186 10.1038/nature02924 (Pubitemid 39329586)
35. Greten F. R., Eckmann L., Greten T. F., Park J. M., Li Z.-W., Egan L. J., Kagnoff M. F., Karin M., IKK β links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004 118 3 285 296 2-s2.0-4043088499 10.1016/j.cell.2004.07.013 (Pubitemid 39061110)
36. Grivennikov S. I., Greten F. R., Karin M., Immunity, inflammation, and cancer. Cell 2010 140 6 883 899 2-s2.0-77950346282 10.1016/j.cell.2010.01.025
37. Moore R. J., Owens D. M., Stamp G., Mice deficient in tumour necrosis factor-alpha are resistant to skin carcinogenesis. Nature Medicine 1999 5 7 828 831 (Pubitemid 29318619)
38. Voronov E., Shouval D. S., Krelin Y., IL-1 is required for tumour invasiveness and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 2003 100 5 2645 2650 10.1073/pnas.0437939100 (Pubitemid 36297552)
39. Enzler T., Gillessen S., Manis J. P., Ferguson D., Fleming J., Alt F. W., Mihm M., Dranoff G., Deficiencies of GM-CSF and interferon γ link inflammation and cancer. Journal of Experimental Medicine 2003 197 9 1213 1219 2-s2.0-0038558189 10.1084/jem.20021258 (Pubitemid 36570077)
40. Didonato J. A., Mercurio F., Karin M., NF- B and the link between inflammation and cancer. Immunological Reviews 2012 246 1 379 400 2-s2.0-84858718448 10.1111/j.1600-065X.2012.01099.x
41. Dranoff G., Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews Cancer 2004 4 1 11 22 2-s2.0-0347302952 (Pubitemid 38111131)
42. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., Medzhitov R., Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004 118 2 229 241 2-s2.0-3242664636 10.1016/j.cell.2004.07.002 (Pubitemid 38962578)
43. Rayburn E. R., Ezell S. J., Zhang R., Anti-inflammatory agents for cancer therapy. Molecular and Cellular Pharmacology 2009 1 1 29 43 2-s2.0-77953445296 10.4255/mcpharmacol.09.05
44. Langman M. J. S., Cheng K. K., Gilman E. A., Lancashire R. J., Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. British Medical Journal 2000 320 7250 1642 1646 2-s2.0-0034679222 (Pubitemid 30364636)
45. Cuzick J., Otto F., Baron J. A., Brown P. H., Burn J., Greenwald P., Jankowski J., La Vecchia C., Meyskens F., Senn H. J., Thun M., Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. The Lancet Oncology 2009 10 5 501 507 2-s2.0-65349152488 10.1016/S1470-2045(09)70035-X
46. Khan Z., Khan N., Tiwari R. P., Sah N. K., Prasad G. B. K. S., Bisen P. S., Biology of Cox-2: an application in cancer therapeutics. Current Drug Targets 2011 12 7 1082 1093 2-s2.0-79958088295
47. Dorff T. B., Goldman B., Pinski J. K., Mack P. C., Lara P. N. Jr., Van Veldhuizen P. J. Jr., Quinn D. I., Vogelzang N. J., Thompson I. M. Jr., Hussain M. H. A., Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clinical Cancer Research 2010 16 11 3028 3034 2-s2.0-77953091816 10.1158/1078-0432.CCR-09-3122
48. Fizazi K., De Bono J. S., Flechon A., Heidenreich A., Voog E., Davis N. B., Qi M., Bandekar R., Vermeulen J. T., Cornfeld M., Hudes G. R., Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer 2012 48 1 85 93 2-s2.0-83255176682 10.1016/j.ejca.2011.10.014
49. Feldmann M., Development of anti-TNF therapy for rheumatoid arthritis. Nature Reviews Immunology 2002 2 5 364 371 2-s2.0-0036584028 (Pubitemid 37328759)
50. Feldmann M., Maini R. N., TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine 2003 9 10 1245 1250 2-s2.0-0142041982 10.1038/nm939 (Pubitemid 37279838)
51. Sandborn W. J., Hanauer S. B., Antitumor necrosis factor therapy for Inflammatory Bowel Disease: a review of agents, pharmacology, clinical results, and safety. Inflammatory Bowel Diseases 1999 5 2 119 133 2-s2.0-0033125226
52. Qi F., Li A., Inagaki Y., Kokudo N., Tamura S., Nakata M., Tang W., Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. International Immunopharmacology 2011 11 3 342 349 2-s2.0-79952101058 10.1016/j.intimp.2010.12.007
53. Qi F., Li A., Inagaki Y., Gao J., Li J., Kokudo N., Li X.-K., Tang W., Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Bioscience trends 2010 4 6 297 307 2-s2.0-79955655749
54. Chen K., Jensen H., Armacognostic study of Ch'an Su, the dried venom of the Chinese toad. Journal of the American Pharmaceutical Association 1929 18 3 244 251
55. Gomes A., Bhattacharjee P., Mishra R., Biswas A. K., Dasgupta S. C., Giri B., Debnath A., Gupta S. D., Das T., Gomes A., Anticancer potential of animal venoms and toxins. Indian Journal of Experimental Biology 2010 48 2 93 103 2-s2.0-77952980253
56. Wang L., Raju U., Milas L., Molkentine D., Zhang Z., Yang P., Cohen L., Meng Z., Liao Z., Huachansu, containing cardiac glycosides, enhances radiosensitivity of human lung cancer cells. Anticancer Research 2011 31 6 2141 2148 2-s2.0-79960469869
57. Wu W. Y., Chai X. S., Liu W. S., Synergistic anti-cancer effects and mechanisms of huachansu plus vinorelbine on Lewis lung cancer cell in mice. China Oncology 2004 14 4
58. Cui Y., Zuo X., Qin S., Clinical trial of Huachansu injection for anti-cancer efficacy. Jiangsu Journal of Clinical Medicine 2002 6 5 505 508
59. Meng Z., Yang P., Shen Y., Bei W., Zhang Y., Ge Y., Newman R. A., Cohen L., Liu L., Thornton B., Chang D. Z., Liao Z., Kurzrock R., Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer 2009 115 22 5309 5318 2-s2.0-70449376872 10.1002/cncr.24602
60. Xie X., Huang X., Li J., Efficacy and safety of Huachansu combined with chemotherapy in advanced gastric cancer: a meta-analysis. Medical Hypotheses 2013 81 2 243 250 10.1016/j.mehy.2013.04.038
61. Wang L., Raju U., Milas L., Molkentine D., Zhang Z., Yang P., Cohen L., Meng Z., Liao Z., Huachansu, containing cardiac glycosides, enhances radiosensitivity of human lung cancer cells. Anticancer Research 2011 31 6 2141 2148 2-s2.0-79960469869
62. Wang D.-L., Qi F.-H., Tang W., Wang F.-S., Chemical constituents and bioactivities of the skin of Bufo bufo gargarizans cantor. Chemistry and Biodiversity 2011 8 4 559 567 2-s2.0-79954544599 10.1002/cbdv.201000283
63. Gao H., Zehl M., Leitner A., Wu X., Wang Z., Kopp B., Comparison of toad venoms from different Bufo species by HPLC and LC-DAD-MS/MS. Journal of Ethnopharmacology 2010 131 2 368 376 2-s2.0-77956263655 10.1016/j.jep.2010.07. 017
64. Newman R. A., Yang P., Pawlus A. D., Block K. I., Cardiac glycosides as novel cancer therapeutic agents. Molecular Interventions 2008 8 1 36 49 2-s2.0-40849124038 10.1124/mi.8.1.8 (Pubitemid 351398451)
65. Ye J., Chen S., Maniatis T., Cardiac glycosides are potent inhibitors of interferon- β gene expression. Nature Chemical Biology 2011 7 1 25 33 2-s2.0-78650510234 10.1038/nchembio.476
66. Yang Q., Huang W., Jozwik C., Lin Y., Glasman M., Caohuy H., Srivastava M., Esposito D., Gillette W., Hartley J., Pollard H. B., Cardiac glycosides inhibit TNF- /NF- B signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor. Proceedings of the National Academy of Sciences of the United States of America 2005 102 27 9631 9636 2-s2.0-22144480948 10.1073/pnas.0504097102 (Pubitemid 40981732)
67. Manna S. K., Sreenivasan Y., Sarkar A., Cardiac glycoside inhibits IL-8-induced biological responses by downregulating IL-8 receptors through altering membrane fluidity. Journal of Cellular Physiology 2006 207 1 195 207 2-s2.0-33644918063 10.1002/jcp.20555
68. Afaq F., Saleem M., Aziz M. H., Mukhtar H., Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion markers in CD-1 mouse skin by oleandrin. Toxicology and Applied Pharmacology 2004 195 3 361 369 2-s2.0-1542407656 10.1016/j.taap.2003.09.027 (Pubitemid 38338657)
69. Gao H., Zehl M., Leitner A., Wu X., Wang Z., Kopp B., Comparison of toad venoms from different Bufo species by HPLC and LC-DAD-MS/MS. Journal of Ethnopharmacology 2010 131 2 368 376 2-s2.0-77956263655 10.1016/j.jep.2010.07. 017
70. Li J., Ma X., Li F., Wang J., Chen H., Wang G., Lv X., Sun C., Jia J., Preparative separation and purification of bufadienolides from Chinese traditional medicine of ChanSu using high-speed counter-current chromatography. Journal of Separation Science 2010 33 9 1325 1330 2-s2.0-77952143827 10.1002/jssc.200900782
71. Ye M., Guo H., Guo H., Han J., Guo D., Simultaneous determination of cytotoxic bufadienolides in the Chinese medicine ChanSu by high-performance liquid chromatography coupled with photodiode array and mass spectrometry detections. Journal of Chromatography B 2006 838 2 86 95 2-s2.0-33745387518 10.1016/j.jchromb.2006.04.042 (Pubitemid 43946741)
72. Su Y. H., Huang X. Q., Zhang D. Z., HPLC separation and determination of bufadienolide in cinobufacini injection. Chinese Traditional Patent Medicine 2003 25 24 27
73. Wu X., Zhao H., Wang H., Simultaneous determination of eight bufadienolides in cinobufacini injection by HPLC coupled with triple quadrupole mass spectrometry. Journal of Separation Science 2012 35 15 1893 1898
74. Dong Y.-Q., Ma W.-L., Gu J.-B., Zheng W.-L., Effect of cinobufagin on nuclear factor-kappaB pathway in HepG2 cells. Nan Fang Yi Ke Da Xue Xue Bao 2010 30 1 137 139 2-s2.0-80051568204
75. Jiang Y., Zhang Y., Luan J., Duan H., Zhang F., Yagasaki K., Zhang G., Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action. Cytotechnology 2010 62 6 573 583 2-s2.0-78651518059 10.1007/s10616-010-9310-0
76. Chen Y. Y., Lu H. F., Hsu S. C., Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK-Hep1 cells through the inhibitions of NF-kB and matrix metalloproteinase-2/-9-signaling pathways. Environmental Toxicology 2013 10.1002/tox.21896
77. Bhuiyan M. B. A., Fant M. E., Dasgupta A., Study on mechanism of action of Chinese medicine Chan Su: dose-dependent biphasic production of nitric oxide in trophoblastic BeWo cells. Clinica Chimica Acta 2003 330 1-2 179 184 2-s2.0-0037375729 10.1016/S0009-8981(03)00047-0 (Pubitemid 36287646)
78. Kim M. H., Lyu J. H., Lyu S. A., Inhibitory effect of Chan-Su on the secretion of PGE2 and NO in LPS-stimulated BV2 microglial cells. Korean Journal of Oriental Physiology and Pathology 2008 22 5 1315 1321
79. Ko W. S., Park T. Y., Park C., Kim Y. H., Yoon H. J., Lee S. Y., Hong S. H., Choi B. T., Lee Y. T., Choi Y. H., Induction of apoptosis by Chan Su, a traditional Chinese medicine, in human bladder carcinoma T24 cells. Oncology reports 2005 14 2 475 480 2-s2.0-24744443929
80. Wang J.-Y., Chen L., Zheng Z., Wang Q., Guo J., Xu L., Cinobufocini inhibits NF- B and COX-2 activation induced by TNF- in lung adenocarcinoma cells. Oncology Reports 2012 27 5 1619 1624 2-s2.0-84858202917 10.3892/or.2012.1647
81. Ma H., Kou J., Zhu D., Yan Y., Yu B., Liu-Shen-Wan, a traditional Chinese medicine, improves survival in sepsis induced by cecal ligation and puncture via reducing TNF- levels, MDA content and enhancing macrophage phagocytosis. International Immunopharmacology 2006 6 8 1355 1362 2-s2.0-33744966572 10.1016/j.intimp.2006.03.003 (Pubitemid 43868184)
82. Andrew P. J., Mayer B., Enzymatic function of nitric oxide synthases. Cardiovascular Research 1999 43 3 521 531 2-s2.0-0033567065 10.1016/S0008- 6363(99)00115-7 (Pubitemid 29369251)
83. Korhonen R., Lahti A., Kankaanranta H., Moilanen E., Nitric oxide production and signaling in inflammation. Current Drug Targets 2005 4 4 471 479 2-s2.0-22944457184 10.2174/1568010054526359 (Pubitemid 41052412)
84. Singh S., Gupta A. K., Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemotherapy and Pharmacology 2011 67 6 1211 1224 2-s2.0-79959582633 10.1007/s00280-011-1654-4
85. Lala P. K., Chakraborty C., Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncology 2001 2 3 149 156 2-s2.0-0035296203 10.1016/S1470-2045(00)00256-4 (Pubitemid 33585926)
86. Hong Z., Chan K., Yeung H. W., Simultaneous determination of bufadienolides in the traditional Chinese medicine preparation, Liu-Shen-Wan, by liquid chromatography. Journal of Pharmacy and Pharmacology 1992 44 12 1023 1026 2-s2.0-0026449022
87. Cunha Filho G. A., Schwartz C. A., Resck I. S., Murta M. M., Lemos S. S., Castro M. S., Kyaw C., Pires O. R. Jr., Leite J. R. S., Bloch C. Jr., Schwartz E. F., Antimicrobial activity of the bufadienolides marinobufagin and telocinobufagin isolated as major components from skin secretion of the toad Bufo rubescens. Toxicon 2005 45 6 777 782 2-s2.0-20144389436 10.1016/j.toxicon.2005.01.017 (Pubitemid 40432602)
88. Cui X., Inagaki Y., Xu H., Wang D., Qi F., Kokudo N., Fang D., Tang W., Anti-hepatitis B virus activities of cinobufacini and its active components bufalin and cinobufagin in HepG2.2.15 Cells. Biological and Pharmaceutical Bulletin 2010 33 10 1728 1732 2-s2.0-77958001851
89. Ehrke M. J., Immunomodulation in cancer therapeutics. International Immunopharmacology 2003 3 8 1105 1119 2-s2.0-0038307758 10.1016/S1567-5769(03) 00021-3 (Pubitemid 36830855)
90. Wang X.-L., Zhao G.-H., Zhang J., Shi Q.-Y., Guo W.-X., Tian X.-L., Qiu J.-Z., Yin L.-Z., Deng X.-M., Song Y., Immunomodulatory effects of cinobufagin isolated from Chan Su on activation and cytokines secretion of immunocyte in vitro. Journal of Asian Natural Products Research 2011 13 5 383 392 2-s2.0-79957861959 10.1080/10286020.2011.565746
91. Cao Y., Song Y., An N., Zeng S., Wang D., Yu L., Zhu T., Zhang T., Cui J., Zhou C., Deng X., The effects of telocinobufagin isolated from Chan Su on the activation and cytokine secretion of immunocytes in vitro. Fundamental and Clinical Pharmacology 2009 23 4 457 464 2-s2.0-68749098702 10.1111/j.1472-8206. 2009.00696.x
92. Liu X., Liu K., Yang Y., Effects of cinobufacini on the growth of Hela cell and IL-2 production of murine spleen lymphocytes. The Journal of Immunology 2005 21 S132 S135
93. Li C., Hashimi S. M., Cao S., The mechanisms of chansu in inducing efficient apoptosis in colon cancer cells. Evidence-Based Complementary and Alternative Medicine 2013 2013 11 10.1155/2013/849054 849054
94. Yun H. R., Yoo H. S., Shin D. Y., Hong S. H., Kim J.-H., Cho C. K., Choi Y. H., Apoptosis induction of human lung carcinoma cells by Chan Su (Venenum Bufonis) through activation of caspases. Journal of Acupuncture and Meridian Studies 2009 2 3 210 217 2-s2.0-69949084357 10.1016/S2005-2901(09)60057-1
95. Wang J., Jin Y., Xu Z., Zheng Z., Wan S., Involvement of caspase-3 activity and survivin downregulation in cinobufocini-induced apoptosis in A 549 cells. Experimental Biology and Medicine 2009 234 5 566 572 2-s2.0-66149145921 10.3181/0811-RM-326
96. Yu C.-H., Kan S.-F., Pu H.-F., Chien E. J., Wang P. S., Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Science 2008 99 12 2467 2476 2-s2.0-57349105671 10.1111/j.1349-7006.2008.00966.x
97. Yeh J.-Y., Huang W. J., Kan S.-F., Wang P. S., Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 2003 54 2 112 124 2-s2.0-0037304261 10.1002/pros.10172 (Pubitemid 36120327)
98. Gowda R. M., Cohen R. A., Khan I. A., Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications. Heart 2003 89 4 e14 2-s2.0-0037394265
99. Hu K., Zhu L., Liang H., Hu F., Feng J., Improved antitumor efficacy and reduced toxicity of liposomes containing bufadienolides. Archives of Pharmacal Research 2011 34 9 1487 1494 2-s2.0-80755125538 10.1007/s12272-011-0910-9
100. Li F., Weng Y., Wang L., He H., Yang J., Tang X., The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers. International Journal of Pharmaceutics 2010 393 1-2 204 212 2-s2.0-77953358025 10.1016/j.ijpharm.2010. 04.005
101. Ma H., Zhou J., Jiang J., Duan J., Xu H., Tang Y., Lv G., Zhang J., Zhan Z., Ding A., The novel antidote Bezoar Bovis prevents the cardiotoxicity of Toad (Bufo bufo gargarizans Canto) Venom in mice. Experimental and Toxicologic Pathology 2012 64 5 417 423 2-s2.0-84860489636 10.1016/j.etp.2010.10.007
102. Cao S., Cripps A., Wei M. Q., New strategies for cancer gene therapy: progress and opportunities. Clinical and Experimental Pharmacology and Physiology 2010 37 1 108 114 2-s2.0-74049091788 10.1111/j.1440-1681.2009.05268.x